Published in Antimicrob Agents Chemother on December 17, 2007
Systematic phenotyping of a large-scale Candida glabrata deletion collection reveals novel antifungal tolerance genes. PLoS Pathog (2014) 1.98
Fungal echinocandin resistance. Fungal Genet Biol (2009) 1.78
Antifungal resistance and new strategies to control fungal infections. Int J Microbiol (2011) 1.44
Chitin synthesis and fungal pathogenesis. Curr Opin Microbiol (2010) 1.30
Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob Agents Chemother (2011) 1.25
Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin. Antimicrob Agents Chemother (2010) 1.21
Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob Agents Chemother (2012) 1.11
Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. Antimicrob Agents Chemother (2011) 1.10
Surface stress induces a conserved cell wall stress response in the pathogenic fungus Candida albicans. Eukaryot Cell (2012) 1.04
FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy. Antimicrob Agents Chemother (2010) 1.01
Differential Aspergillus lentulus echinocandin susceptibilities are Fksp independent. Antimicrob Agents Chemother (2010) 0.99
Cell wall chitosaccharides are essential components and exposed patterns of the phytopathogenic oomycete Aphanomyces euteiches. Eukaryot Cell (2008) 0.97
Mechanisms of echinocandin antifungal drug resistance. Ann N Y Acad Sci (2015) 0.84
The Rho1 GTPase-activating protein CgBem2 is required for survival of azole stress in Candida glabrata. J Biol Chem (2011) 0.82
Caspofungin Treatment of Aspergillus fumigatus Results in ChsG-Dependent Upregulation of Chitin Synthesis and the Formation of Chitin-Rich Microcolonies. Antimicrob Agents Chemother (2015) 0.80
Assessment of caspofungin susceptibility of Candida glabrata by the Etest®, CLSI, and EUCAST methods, and detection of FKS1 and FKS2 mutations. Eur J Clin Microbiol Infect Dis (2014) 0.77
Micafungin in the treatment of invasive candidiasis and invasive aspergillosis. Infect Drug Resist (2009) 0.76
Genetic Drivers of Multidrug Resistance in Candida glabrata. Front Microbiol (2016) 0.75
KRE5 Suppression Induces Cell Wall Stress and Alternative ER Stress Response Required for Maintaining Cell Wall Integrity in Candida glabrata. PLoS One (2016) 0.75
Identification of Genes in Candida glabrata Conferring Altered Responses to Caspofungin, a Cell Wall Synthesis Inhibitor. G3 (Bethesda) (2016) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
The function of chitin synthases 2 and 3 in the Saccharomyces cerevisiae cell cycle. J Cell Biol (1991) 3.65
Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase. Mol Cell Biol (1995) 3.27
Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob Agents Chemother (1998) 2.43
The protein kinase C-mediated MAP kinase pathway involved in the maintenance of cellular integrity in Saccharomyces cerevisiae. Mol Microbiol (1999) 2.31
Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother (2004) 2.28
Temperature-induced expression of yeast FKS2 is under the dual control of protein kinase C and calcineurin. Mol Cell Biol (1998) 2.22
Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother (2006) 2.19
The yeast protein kinase C cell integrity pathway mediates tolerance to the antifungal drug caspofungin through activation of Slt2p mitogen-activated protein kinase signaling. Eukaryot Cell (2003) 2.00
The PKC, HOG and Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. Mol Microbiol (2007) 2.00
Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae. J Biol Chem (2003) 1.94
Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. Antimicrob Agents Chemother (2007) 1.76
Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother (2005) 1.75
Chs1p and Chs3p, two proteins involved in chitin synthesis, populate a compartment of the Saccharomyces cerevisiae endocytic pathway. Mol Biol Cell (1996) 1.72
In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother (2007) 1.47
Genomic approach to identification of mutations affecting caspofungin susceptibility in Saccharomyces cerevisiae. Antimicrob Agents Chemother (2004) 1.34
Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob Agents Chemother (2006) 1.34
Promoter-dependent disruption of genes: simple, rapid, and specific PCR-based method with application to three different yeast. Curr Genet (2005) 1.25
Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae. Antimicrob Agents Chemother (2002) 1.14
In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemother (2006) 1.06
Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. Antimicrob Agents Chemother (2005) 1.00
Caspofungin in combination with amphotericin B against Candida glabrata. Antimicrob Agents Chemother (2005) 0.98
Effects of cilofungin (LY121019) on carbohydrate and sterol composition of Candida albicans. Eur J Clin Microbiol Infect Dis (1989) 0.95
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother (2008) 2.44
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother (2008) 2.38
Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrob Agents Chemother (2005) 2.35
Recommended education for pharmacists as competitive clinical scientists. Pharmacotherapy (2009) 2.31
ASA failure: does the combination ASA/clopidogrel confer better long-term vascular protection? Neurology (2014) 2.08
Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae. J Biol Chem (2003) 1.94
The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog (2007) 1.94
Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol Microbiol (2008) 1.90
Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor. Antimicrob Agents Chemother (2004) 1.76
Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother (2005) 1.69
A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. Eukaryot Cell (2008) 1.67
Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome-wide expression studies. Mol Microbiol (2006) 1.67
Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob (2012) 1.55
Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease--a placebo-controlled pilot study. J Sex Med (2007) 1.51
Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation. Antimicrob Agents Chemother (2002) 1.51
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother (2008) 1.47
Voriconazole: a new triazole antifungal agent. Ann Pharmacother (2003) 1.47
Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. Antimicrob Agents Chemother (2008) 1.46
Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med (2003) 1.41
Detection of gliotoxin in experimental and human aspergillosis. Infect Immun (2005) 1.38
Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother (2008) 1.37
An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans. Antimicrob Agents Chemother (2009) 1.36
Genome-wide expression and location analyses of the Candida albicans Tac1p regulon. Eukaryot Cell (2007) 1.35
Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. J Antimicrob Chemother (2004) 1.33
Identification of the Candida albicans Cap1p regulon. Eukaryot Cell (2009) 1.29
Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans. Antimicrob Agents Chemother (2011) 1.24
Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med (2006) 1.21
Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia (2010) 1.21
In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicrob Agents Chemother (2005) 1.20
Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae. Antimicrob Agents Chemother (2009) 1.19
Frequency and species distribution of gliotoxin-producing Aspergillus isolates recovered from patients at a tertiary-care cancer center. J Clin Microbiol (2005) 1.17
Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure. Antimicrob Agents Chemother (2013) 1.16
Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryot Cell (2012) 1.16
Murine model of invasive aspergillosis. Methods Mol Med (2005) 1.15
Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance. Antimicrob Agents Chemother (2012) 1.13
Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. J Infect Dis (2005) 1.13
Recent insights into the mechanisms of antifungal resistance. Curr Infect Dis Rep (2006) 1.10
Genomewide expression profile analysis of the Candida glabrata Pdr1 regulon. Eukaryot Cell (2010) 1.07
Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother (2008) 1.07
In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemother (2006) 1.06
Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains. Antimicrob Agents Chemother (2008) 1.06
Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm (2008) 1.05
Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy (2007) 1.05
Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections. J Am Board Fam Med (2010) 1.05
The echinocandin "target" identified by cross-linking is a homolog of Pil1 and Lsp1, sphingolipid-dependent regulators of cell wall integrity signaling. Antimicrob Agents Chemother (2004) 1.02
Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agents. Antimicrob Agents Chemother (2010) 1.02
New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species. Antimicrob Agents Chemother (2011) 1.00
Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms. Int J Antimicrob Agents (2005) 0.98
In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J Antimicrob Chemother (2009) 0.96
Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction. Pharmacotherapy (2006) 0.96
Transcriptome profile of the vascular endothelial cell response to Candida albicans. J Infect Dis (2008) 0.96
Proteomic analysis of azole resistance in Candida albicans clinical isolates. Antimicrob Agents Chemother (2004) 0.95
CRS-MIS in Candida glabrata: sphingolipids modulate echinocandin-Fks interaction. Mol Microbiol (2012) 0.95
Candida glabrata mutants demonstrating paradoxical reduced caspofungin susceptibility but increased micafungin susceptibility. Antimicrob Agents Chemother (2011) 0.95
Differential requirement of the transcription factor Mcm1 for activation of the Candida albicans multidrug efflux pump MDR1 by its regulators Mrr1 and Cap1. Antimicrob Agents Chemother (2011) 0.94
Pravastatin versus simvastatin for prevention of contrast-induced nephropathy. J Cardiovasc Pharmacol Ther (2011) 0.94
Coculture of THP-1 human mononuclear cells with Candida albicans results in pronounced changes in host gene expression. J Infect Dis (2005) 0.94
Impact of new antifungal breakpoints on antifungal resistance in Candida species. J Clin Microbiol (2014) 0.94
Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit. Clin Ther (2010) 0.92
Genome-wide expression profiling of the response to ciclopirox olamine in Candida albicans. J Antimicrob Chemother (2005) 0.91
The transcription factor Ndt80 does not contribute to Mrr1-, Tac1-, and Upc2-mediated fluconazole resistance in Candida albicans. PLoS One (2011) 0.91
Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis. Antimicrob Agents Chemother (2013) 0.91
In vitro activity of carbapenems alone and in combination with amikacin against KPC-producing Klebsiella pneumoniae. J Clin Med Res (2011) 0.91
Proteomic analysis of experimentally induced azole resistance in Candida glabrata. J Antimicrob Chemother (2006) 0.90
Clinical Upate. Managing the challenges of hypothyroidism. J Fam Pract (2006) 0.90
Effects of amphotericin B and caspofungin on histamine expression. Pharmacotherapy (2003) 0.90
Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J Infect (2007) 0.90
Influence of hydroxypropyl methylcellulose polymer on in vitro and in vivo performance of controlled release tablets containing alprazolam. Eur J Pharm Biopharm (2003) 0.90
Variability in polyene content and cellular toxicity among deoxycholate amphotericin B formulations. Pharmacotherapy (2003) 0.90
Clonal dissemination of Klebsiella pneumoniae carbapenemase KPC-3 in Long Beach, California. J Clin Microbiol (2009) 0.89
Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans. J Med Microbiol (2002) 0.89
ROX1 and ERG regulation in Saccharomyces cerevisiae: implications for antifungal susceptibility. Eukaryot Cell (2002) 0.89
Topological and mutational analysis of Saccharomyces cerevisiae Fks1. Eukaryot Cell (2012) 0.88
Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. J Antimicrob Chemother (2008) 0.87
Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Clin Ther (2004) 0.86
The Changing Epidemiology of Oropharyngeal Candidiasis in Patients with HIV/AIDS in the Era of Antiretroviral Therapy. AIDS Res Treat (2012) 0.86
Identification of genes differentially expressed in association with reduced azole susceptibility in Saccharomyces cerevisiae. J Antimicrob Chemother (2003) 0.86
Aspirin resistance: an evaluation of current evidence and measurement methods. Pharmacotherapy (2005) 0.85
Functional dissection of a Candida albicans zinc cluster transcription factor, the multidrug resistance regulator Mrr1. Eukaryot Cell (2011) 0.85
Antibacterials as adjuncts to incision and drainage for adults with purulent methicillin-resistant Staphylococcus aureus (MRSA) skin infections. Drugs (2012) 0.85
National Pharmacy Cardiovascular Council treatment guidelines for the management of type 2 diabetes mellitus: toward better patient outcomes and new roles for pharmacists. Pharmacotherapy (2002) 0.85
A murine model of Cryptococcus gattii meningoencephalitis. J Antimicrob Chemother (2012) 0.85
Antimicrobial peptide MUC7 12-mer activates the calcium/calcineurin pathway in Candida albicans. FEMS Yeast Res (2010) 0.84
Clinical epidemiology of carbapenem-resistant enterobacteriaceae in community hospitals: a case-case-control study. Ann Pharmacother (2013) 0.84
Detection and measurement of fungal burden in a guinea pig model of invasive pulmonary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1,3)-β-D-glucan detection. J Clin Microbiol (2011) 0.84
Characterization and pharmacokinetic analysis of aerosolized aqueous voriconazole solution. Eur J Pharm Biopharm (2009) 0.84
Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm Res (2006) 0.84
Single dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm (2006) 0.84
In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother (2006) 0.83